In a desperate attempt to control the ongoing Ebola outbreak in West Africa, the World Health Organization is appealing to drug companies and international regulatory bodies to work together to get experimental therapies and vaccines out of the lab and into the clinic as soon as possible.
Facing dwindling sales and a thin late-stage pipeline, Merck KGaA is looking to accelerate its efforts in allergy drug development, signing a deal with an Austrian biotech with hopes of quickly seeding new programs in the field.
Endoscopic surgery isn't usually associated with diabetes, but Fractyl Laboratories yesterday announced encouraging clinical trial results for its endoscopic procedure to treat Type 2 diabetes and revealed a $40 million Series C financing round led by investment firm Mithril Capital Management.
OncoMed is moving on from tandem setbacks in its cancer pipeline now that the FDA has removed its final clinical hold on one of the biotech's oncology candidates, clearing it to resume enrollment in a Phase I study.
Edison Pharmaceuticals' in-development rare disease treatment missed its primary endpoint in a mid-stage trial, denting the company's plans for an expansive take on CNS R&D.
As cardiac devicemakers search for innovative ways to streamline products for patients, Swiss researchers have developed a self-powered pacemaker modeled after an automatic wristwatch that could provide an alternative to traditional pacing systems.
Tiny biotech Mapp Biopharmaceutical made global headlines this summer when its early-stage Ebola treatment helped rescue a few patients from the deadly virus, and now the U.S. government is ponying up funds to help the company get its drug into clinical trials.
A while ago, there was talk of a dreaded biotech bubble, and Novartis' decision to slam the breaks on its RNA interference research was making waves. But lately, the talk has turned positive on the promising yet unproven treatment paradigm, which utilizes RNAi to deliver gene-based therapy.
Creating the materials used for some of the most intricate nanostructures in drug delivery sometimes requires going back to the basics. In the case of researchers at the University of Oregon and the Berkeley Lab, this meant looking at the interaction between oil and water, developing nanosheets that could be used to compile delivery vehicles down the road.
Expect more needle-free vaccines to come to market on the heels of the first approval of a needle-free delivery system for the inactivated flu vaccine, market research firm Frost & Sullivan says.